D2 autoreceptor switches CB2 receptor effects on [3 H]-dopamine release in the striatum

Synapse. 2020 Mar;74(3):e22139. doi: 10.1002/syn.22139. Epub 2019 Oct 19.

Abstract

CB2 receptors (CB2 R) are expressed in midbrain neurons. To evidence the control of dopamine release in dorsal striatum by CB2 R, we performed experiments of [3 H]-dopamine release in dorsal striatal slices. We found a paradoxical increase in K+ -induced [3 H]-dopamine release by CB2 R activation with GW 833972A and JWH 133 two selective agonist. To understand the mechanism involved, we tested for a role of the D2 autoreceptor in this effect; because in pallidal structures, the inhibitory effect of CB1 receptors (CB1 R) on GABA release is switched to a stimulatory effect by D2 receptors (D2 R). We found that the blockade of D2 autoreceptors with sulpiride prevented the stimulatory effect of CB2 R activation; in fact, under this condition, CB2 R decreased dopamine release, indicating the role of the D2 autoreceptor in the paradoxical increase. We also found that the effect occurs in nigrostriatal terminals, since lesions with 6-OH dopamine in the middle forebrain bundle prevented CB2 R effects on release. In addition, D2 -CB2 R interaction promoted cAMP accumulation, and the increase in [3 H]-dopamine release was prevented by PKA blockade. D2 -CB2 R coprecipitation and proximity ligation assay studies indicated a close interaction of receptors that could participate in the observed effects. Finally, intrastriatal injection of CB2 R agonist induced contralateral turning in amphetamine-treated rats, which was prevented by sulpiride, indicating the role of the interaction in motor behavior. Thus, these data indicate that the D2 autoreceptor switches, from inhibitory to stimulatory, the CB2 R effects on dopamine release, involving the cAMP → PKA pathway in nigrostriatal terminals.

Keywords: CB2 receptors; D2-CB2; dopamine release; interaction substantia nigra pars compacta; motor behavior.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphetamine / pharmacology
  • Animals
  • Cannabinoid Receptor Agonists / pharmacology
  • Cannabinoids / pharmacology
  • Cells, Cultured
  • Corpus Striatum / cytology
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism*
  • Cyclic AMP / metabolism
  • Dopamine / metabolism*
  • Dopamine D2 Receptor Antagonists / pharmacology
  • Dopaminergic Neurons / drug effects
  • Dopaminergic Neurons / metabolism
  • Dopaminergic Neurons / physiology
  • Male
  • Movement
  • Presynaptic Terminals / drug effects
  • Presynaptic Terminals / metabolism
  • Presynaptic Terminals / physiology
  • Pyridines / pharmacology
  • Pyrimidines / pharmacology
  • Rats
  • Rats, Wistar
  • Receptor, Cannabinoid, CB2 / agonists
  • Receptor, Cannabinoid, CB2 / metabolism*
  • Receptors, Dopamine D2 / metabolism*
  • Substantia Nigra / cytology
  • Substantia Nigra / drug effects
  • Substantia Nigra / metabolism*
  • Sulpiride / pharmacology

Substances

  • Cannabinoid Receptor Agonists
  • Cannabinoids
  • Dopamine D2 Receptor Antagonists
  • GW833972A
  • Pyridines
  • Pyrimidines
  • Receptor, Cannabinoid, CB2
  • Receptors, Dopamine D2
  • Sulpiride
  • Amphetamine
  • Cyclic AMP
  • 1,1-dimethylbutyl-1-deoxy-Delta(9)-THC
  • Dopamine